Advisory Committee on Health Research, chaired the WHO Committees on Leprosy Research and Tuberculosis Research, and chaired the Scientific and Technical Advisory Committee of the United Nations Development Programme (UNDP)/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. He is also a member of the Innovation Working Group under the U.N. Secretary General’s Joint Effort to Improve the Health of Women and Children. Dr. Bloom also serves on the Scientific Advisory Boards of the Earth Institute at Columbia University, the Doris Duke Charitable Foundation, the City University of New York School of Public Health at Hunter College, and the Howard Hughes Medical Institute-KwaZulu-Natal Research Institute for TB and HIV. In addition, he is an Expert Advisory Group member of the Global Fund-AMFm and Scientific Oversight Group member of the Institute for Health Metrics and Evaluation at the University of Washington, Seattle. He is a member of the Board of Trustees for the Tuberculosis Vaccine Institute (TBVI) and the first Chair of the Board of Trustees and now Chair Emeritus of the International Vaccine Institute (IVI). Most recently, he joined the Advisory Board of the Fogarty International Center at the National Institutes of Health (NIH). He is a graduate of Amherst College (B.S. 1958 and honorary D.Sc. 1990) and Rockefeller University (Ph.D. 1963).

Gail H. Cassell, Ph.D. (Workshop Co-Chair), is a Visiting Professor in the Department of Global Health and Social Medicine, Harvard Medical School, and Vice President of TB Drug Discovery of the nonprofit Infectious Disease Research Institute in Seattle. Dr. Cassell has recently retired as Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company in Indianapolis, Indiana. In this capacity, among other things, she was responsible for initiating and leading the nonprofit Lilly TB Drug Discovery Initiative launched in 2007. In 2003, she was one of two individuals at Eli Lilly who initiated and developed the Lilly Multidrug Resistant Tuberculosis Partnership. The partnership has resulted in company support to date of $135 million and is the largest philanthropic effort in Eli Lilly’s 125-year history. The partnership now involves more than 20 partners, including WHO and CDC. She is the former Vice President of Infectious Diseases Drug Discovery and Clinical Development of Eli Lilly, where she led the programs of a hepatitis C protease inhibitor from the discovery phase to clinical candidate (the compound is now in Phase III clinical trials) and the development of a new antibiotic from clinical development to product decision. Prior to moving to Eli Lilly in 1997, Dr. Cassell was the former Charles H. McCauley Professor and Chair of the Department of Microbiology at the University of Alabama Schools of Medicine and Dentistry at Birmingham, a department that ranked first in research funding from



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement